H1299 Cisplatin-Resistant Multi-Drug Resistant Lung Cancer Model Service

The H1299 Cisplatin-Resistant Multi-Drug Resistant Lung Cancer Model Service provides an in vivo recreation of platinum failure in lung cancer: the intrinsically refractory p53-null, ERCC1-high H1299 tumor is pushed through continuous cisplatin pressure until multi-drug resistance — spanning drug-efflux transporters, enhanced DNA repair, stemness programs, and metastatic gain — is fully established. Alfa Cytology executes this program with sequence-aware cell banking, documented refractoriness baselines, validated intraperitoneal cisplatin dosing sustained to breakthrough, and endpoint analysis that quantifies platinum-adduct burden, repair-pathway activity, efflux-transporter expression, and stemness markers — delivering resistant cohorts whose multi-drug phenotype is confirmed across axes, not asserted.

Overview of H1299 Cisplatin-Resistant Multi-Drug Resistant Lung Cancer Model

Cisplatin, approved in 1978 and still the backbone of platinum-doublet chemotherapy for non-small cell lung cancer, kills by a deceptively simple chemistry: the platinum atom forms intrastrand crosslinks, predominantly 1,2-adducts at guanine dinucleotides, that distort the DNA helix and trigger replication catastrophe and apoptosis. Tumor cells answer with an equally organized defense, and H1299 embodies that defense in its baseline state. Derived from the lymph-node metastasis of a lung adenocarcinoma, H1299 carries a homozygous TP53 deletion — eliminating the p53-dependent apoptotic route through which cisplatin kills most cells — and expresses high levels of ERCC1, the rate-limiting factor of nucleotide excision repair that excises platinum adducts before they become lethal. These two properties alone place H1299 among the most intrinsically cisplatin-refractory NSCLC lines, which is precisely why it has become a preferred substrate for modeling platinum resistance and the multi-drug-resistant phenotype that accompanies it.

Fig 1. TRIM25-AGO2 axis validation in the H1299 cisplatin-resistant MDR model: TRIM25/AGO2 knockdown Westerns in H1299, A549 and DU145, wound-healing and colony-formation assays showing restored drug sensitivity upon silencing the axis. (Zhou, Zihan, et al., 2026)

The resistance logic is best understood as control over the platinum-adduct lifecycle — import, efflux, detoxification, repair, damage tolerance, and the final apoptotic decision. In H1299-derived resistant systems, import is throttled through reduced copper transporter CTR1 expression; efflux and sequestration are handled by copper transporter ATP7A, whose expression in lung cancer cells is controlled by regulators such as miR-495-3p; detoxification proceeds through glutathione and GST-pi conjugation; repair rides on ERCC1/XPF activity, so much so that depleting ERCC1 collapses H1299 clonogenic survival under cisplatin from the micromolar to the sub-micromolar range; and the apoptotic endpoint is pre-empted by constitutive AKT survival signaling in a p53-null background and by Bcl-2 family elevation. Layered above this lifecycle is the multi-drug dimension: the characterized H1299-R selection series, generated by serial cisplatin exposure with detachment-and-reattachment selection, upregulates the ABCG2 efflux transporter together with stemness markers CD133 and CD44, gains migratory and invasive capacity with each selection round, and — critically for in vivo programs — seeds substantially more metastatic lung nodules than parental H1299 in xenograft-bearing mice. Additional H1299 resistance circuitry includes the HOXB13–ABCG1 axis, which confers simultaneous cross-resistance to cisplatin and paclitaxel, and the CHD1L–ABCB1–NF-κB pathway documented across NSCLC models. The model is therefore not merely a cisplatin-failure replica but a multi-drug, pro-metastatic platform in which platinum resensitization, repair-pathway targeting, and stemness-directed combinations can be interrogated together.

Principles of H1299 Cisplatin-Resistant Multi-Drug Resistant Lung Cancer Model Construction

The construction principle is pressure applied along the platinum-adduct lifecycle, with selection acting wherever the lifecycle is weakest — and in H1299, it starts weak in several places at once. Because p53 is absent and ERCC1 is abundant, parental tumors already survive adduct loads that would kill most lines; the experimental question becomes which additional layers of defense emerge under continuous dosing, and whether they remain specific to platinum or generalize to other agents. Two construction routes serve the model: chronic in vivo selection, where xenografts are dosed intraperitoneally until breakthrough at a pre-agreed threshold, and transplantation of in vitro–selected derivatives such as the serial H1299-R series. Both rest on the same discipline: a quantified refractoriness baseline, fixed breakthrough criteria, and an endpoint panel that measures adduct burden, repair activity, efflux-transporter expression, and stemness markers together — the four axes that define multi-drug resistance in this line.

Our Services

Alfa Cytology operates this model as a lifecycle-mapping exercise: H1299 banks are sequence- and marker-verified with documented cisplatin baselines before inoculation, intraperitoneal dosing continues uninterrupted until breakthrough at pre-set thresholds, and endpoint panels quantify adduct burden, ERCC1 activity, ABC transporter expression, and CD133/CD44 stemness together — so the multi-drug resistance your resensitization strategies confront is characterized along every axis that matters.

Workflow of H1299 Cisplatin-Resistant Multi-Drug Resistant Lung Cancer Model Construction

Building multi-drug resistance in an H1299 program is a study in layered defense mechanisms surfacing under sustained platinum pressure. The sequence below follows a typical engagement from bank verification to resistant cohorts annotated across the adduct-lifecycle and stemness axes.

1. Study design and route selection: The plan fixes the construction route — chronic in vivo selection or transplantation of an in vitro–selected derivative — together with group sizes, intraperitoneal dosing schedules, vehicle controls, and the quantitative breakthrough threshold that will define resistance.
2. Cell authentication and baseline profiling: H1299 banks are STR-authenticated and mycoplasma-cleared, p53-null and ERCC1-high status is reconfirmed, and baseline cisplatin IC50 values plus multi-drug sensitivity panels are documented to anchor downstream resistance ratios.
3. In vitro resistance establishment (where selected): Parental cells are stepped through escalating cisplatin exposure over months — optionally with detachment-and-reattachment cycles that enrich for invasive, stem-like survivors — until a stable derivative with documented IC50 shifts and ABCG2/CD133/CD44 upregulation is available for in vivo work.
4. Host preparation and tumor inoculation: Female BALB/c nude mice are randomized and implanted subcutaneously with a standardized inoculum — classically 5 × 10⁶ cells, frequently in Matrigel — and tumors are grown to the pre-specified starting volume.
5. Chronic intraperitoneal cisplatin dosing and breakthrough surveillance: Cisplatin dosing begins at treatment initiation and continues without interruption; tumor dimensions are captured on a fixed schedule, refractoriness is quantified as tumor-growth inhibition relative to vehicle, and breakthrough kinetics are archived.
6. Endpoint characterization: Resistant and control tumors are excised and profiled by H&E with γ-H2AX adduct-burden assessment, ERCC1, ABCB1, ABCG2, GST-pi, CD133/CD44 and Ki-67 immunostaining, and cleaved PARP/caspase-3 apoptosis assays.
7. Data integration and reporting: Tumor-growth kinetics, inhibition ratios, multi-agent IC50 panels, and molecular annotations are consolidated — with repair, efflux, detoxification, and stemness axes separated for interpretation — into the final study report.

Fig 2. H1299 Cisplatin-Resistant Multi-Drug Resistant Lung Cancer Model Construction Workflow.

Case Study-H1299 Cisplatin-Resistant Multi-Drug Resistant Lung Cancer Model Development

Alfa Cytology has applied the H1299 cisplatin-resistance platform in preclinical programs addressing platinum failure and multi-drug-resistant disease in lung cancer, including resensitization strategies and repair-pathway targeting. Studies of this scope have covered sequence-verified bank preparation with multi-agent baseline profiling, subcutaneous xenograft establishment, uninterrupted intraperitoneal cisplatin dosing under pre-agreed breakthrough thresholds, and terminal characterization spanning adduct burden, repair activity, transporter expression, and stemness markers — producing tumor-growth, resistance-ratio and mechanism-axis datasets used for internal decision-making. Further detail can be shared upon request as your program defines its direction.

Why Choose Alfa Cytology?

Multi-drug resistance in H1299 is a layered phenotype — repair, efflux, detoxification, survival, and stemness acting in concert — and a single-axis endpoint panel will misread it. Alfa Cytology measures all layers in every cohort and reports them as an integrated profile.

• STR-authenticated H1299 banks with reconfirmed p53-null/ERCC1-high status and documented multi-agent baselines.
• Both construction routes available: chronic in vivo selection and characterized in vitro–selected derivatives including invasive stem-like variants.
• Validated intraperitoneal dosing logistics sustaining platinum pressure from first dose to breakthrough.
• Pre-agreed quantitative thresholds for declaring cisplatin resistance in every cohort.
• Endpoint panels spanning γ-H2AX, ERCC1, ABCB1, ABCG2, GST-pi, CD133/CD44, Ki-67 and apoptosis markers.
• Strictly preclinical operations — research-stage programs receive our complete attention.
• Integrated reporting that pairs growth kinetics with a four-axis multi-drug resistance profile in one package.

Contact Us

If your pipeline targets platinum-resistant or multi-drug-resistant lung cancer — through resensitization strategies, repair-pathway or efflux inhibition, or stemness-directed combinations — reach out to us to design an H1299 cisplatin-resistant study matched to your mechanism and endpoints. Contact Alfa Cytology today, and our team will return a tailored proposal with cohort designs and projected timelines.

For research use only. Not intended for any clinical use.